IRF7 and systemic sclerosis: Furthermore, expression of TBK1 as well as its downstream mediators IRF3 and IRF7 was observed previously at higher levels in PBMCs from SLE, pSjD and SSc patients compared with controls, suggesting hyperactivity of the TBK1 signalling pathway in these diseases.20